CN107223130A - 作为疫苗载体的三片段沙粒病毒 - Google Patents

作为疫苗载体的三片段沙粒病毒 Download PDF

Info

Publication number
CN107223130A
CN107223130A CN201580073235.6A CN201580073235A CN107223130A CN 107223130 A CN107223130 A CN 107223130A CN 201580073235 A CN201580073235 A CN 201580073235A CN 107223130 A CN107223130 A CN 107223130A
Authority
CN
China
Prior art keywords
arenavirus
segment
orf
particle
utr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580073235.6A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·大卫·平舍韦尔
多伦·梅尔克勒
桑德拉·马格里特·卡尔勒特
马里奥·克罗伊茨费尔特
斯蒂芬妮·加布里埃尔·达尔布雷阿卜杜勒拉赫曼
尼古拉斯·吉恩·佩吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Original Assignee
Universite de Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54545130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107223130(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universite de Geneve filed Critical Universite de Geneve
Publication of CN107223130A publication Critical patent/CN107223130A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10061—Methods of inactivation or attenuation
    • C12N2760/10062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580073235.6A 2014-11-13 2015-11-12 作为疫苗载体的三片段沙粒病毒 Pending CN107223130A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462079493P 2014-11-13 2014-11-13
US62/079,493 2014-11-13
PCT/EP2015/076458 WO2016075250A1 (en) 2014-11-13 2015-11-12 Tri-segmented arenaviruses as vaccine vectors

Publications (1)

Publication Number Publication Date
CN107223130A true CN107223130A (zh) 2017-09-29

Family

ID=54545130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073235.6A Pending CN107223130A (zh) 2014-11-13 2015-11-12 作为疫苗载体的三片段沙粒病毒

Country Status (18)

Country Link
US (3) US10722564B2 (enExample)
EP (2) EP3218504B1 (enExample)
JP (4) JP6805139B2 (enExample)
CN (1) CN107223130A (enExample)
AU (3) AU2015345080B2 (enExample)
CA (1) CA2967720C (enExample)
CY (1) CY1123339T1 (enExample)
DK (2) DK3778903T3 (enExample)
ES (1) ES2811093T3 (enExample)
FI (1) FI3778903T3 (enExample)
HR (1) HRP20201684T1 (enExample)
HU (1) HUE051390T2 (enExample)
LT (2) LT3778903T (enExample)
PL (1) PL3218504T3 (enExample)
PT (1) PT3218504T (enExample)
RS (1) RS60937B1 (enExample)
SI (1) SI3218504T1 (enExample)
WO (1) WO2016075250A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921117A (zh) * 2015-06-10 2018-04-17 霍欧奇帕生物科技股份公司 Hpv疫苗
CN114231562A (zh) * 2021-12-15 2022-03-25 中国科学院武汉病毒研究所 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604695T3 (pl) 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
DK3077519T3 (en) * 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
WO2018045029A1 (en) * 2016-09-02 2018-03-08 The United States Of America, As Represented By The Secretary Of The Army Pan south american arenavirus live attenuated vaccine
CN115948467A (zh) * 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) * 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
JP2019533690A (ja) * 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
CN108611310A (zh) * 2018-04-28 2018-10-02 中国药科大学 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建
CN108977434A (zh) * 2018-07-03 2018-12-11 张罗 鼻腔脱落细胞rna的提取方法
AU2020297011A1 (en) * 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
BR112022024404A2 (pt) 2020-05-29 2023-02-07 Hookipa Biotech Gmbh Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus
KR20230131481A (ko) 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법
WO2022159664A1 (en) * 2021-01-22 2022-07-28 Chan Zuckerberg Biohub, Inc. Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening
BR112023019365A2 (pt) 2021-03-23 2023-12-26 Hookipa Biotech Gmbh Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit
US20240229073A1 (en) 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
JP2024540385A (ja) 2021-11-08 2024-10-31 ホオキパ バイオテック ジーエムビーエイチ 変異型ｋｒａｓ、変異したがんドライバー遺伝子、または腫瘍関連抗原を発現する、がん免疫療法としての改変アレナウイルス粒子
EP4475879A1 (en) 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
JP2025523043A (ja) 2022-07-12 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291688A (zh) * 2005-10-17 2008-10-22 巴斯德研究所 基于慢病毒载体的疫苗
WO2011095760A1 (en) * 2010-02-03 2011-08-11 University Court Of The University Of St Andrews Bunyavirus vaccine
CN103993012A (zh) * 2007-12-27 2014-08-20 苏黎士大学 复制缺陷型沙粒病毒载体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN110042110A (zh) 2012-01-24 2019-07-23 桑福德健康公司 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
BR112017005744B1 (pt) * 2014-09-22 2023-11-28 Regents Of The University Of Minnesota "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo"
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP3365005B1 (en) 2015-10-23 2025-04-09 Institut Pasteur Recombinant mopeia virus and vaccine platform
CN115948467A (zh) 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
IL314272A (en) 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291688A (zh) * 2005-10-17 2008-10-22 巴斯德研究所 基于慢病毒载体的疫苗
CN103993012A (zh) * 2007-12-27 2014-08-20 苏黎士大学 复制缺陷型沙粒病毒载体
WO2011095760A1 (en) * 2010-02-03 2011-08-11 University Court Of The University Of St Andrews Bunyavirus vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENJAMIN BRENNAN等: "The Consequences of Reconfiguring the Ambisense S Genome Segment of Rift Valley Fever Virus on Viral Replication in Mammalian and Mosquito Cells and for Genome Packaging", 《PLOS PATHOGENS》 *
P. J. WICHGERS SCHREUR等: "Creation of Rift Valley Fever Viruses with Four-Segmented Genomes Reveals Flexibility in Bunyavirus Genome Packaging", 《JOURNAL OF VIROLOGY》 *
SEBASTIEN F. EMONET: "Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest", 《PNAS》 *
熊成龙等: "沙粒病毒的研究进展", 《中华疾病控制杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921117A (zh) * 2015-06-10 2018-04-17 霍欧奇帕生物科技股份公司 Hpv疫苗
CN107921117B (zh) * 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
CN114231562A (zh) * 2021-12-15 2022-03-25 中国科学院武汉病毒研究所 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用

Also Published As

Publication number Publication date
ES2811093T3 (es) 2021-03-10
JP2017535267A (ja) 2017-11-30
AU2015345080A1 (en) 2017-06-01
PT3218504T (pt) 2020-09-24
US20210145950A1 (en) 2021-05-20
US10722564B2 (en) 2020-07-28
CA2967720C (en) 2024-01-02
AU2015345080B2 (en) 2022-01-27
HUE051390T2 (hu) 2021-03-01
EP3218504B1 (en) 2020-07-22
EP3778903B1 (en) 2026-01-14
FI3778903T3 (fi) 2026-02-24
RS60937B1 (sr) 2020-11-30
DK3218504T3 (da) 2020-10-19
PL3218504T3 (pl) 2021-02-08
JP2021045154A (ja) 2021-03-25
EP3218504A1 (en) 2017-09-20
US20170319673A1 (en) 2017-11-09
HRP20201684T1 (hr) 2020-12-25
AU2022200061A1 (en) 2022-02-03
JP2023036933A (ja) 2023-03-14
JP6805139B2 (ja) 2020-12-23
SI3218504T1 (sl) 2020-11-30
LT3778903T (lt) 2026-02-10
JP2025170342A (ja) 2025-11-18
HK1244034A1 (en) 2018-07-27
JP7796680B2 (ja) 2026-01-09
DK3778903T3 (da) 2026-02-09
EP3778903A1 (en) 2021-02-17
US20240082376A1 (en) 2024-03-14
LT3218504T (lt) 2020-09-10
WO2016075250A1 (en) 2016-05-19
CY1123339T1 (el) 2021-12-31
CA2967720A1 (en) 2016-05-19
AU2024259760A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
US20240082376A1 (en) Tri-segmented arenaviruses as vaccine vectors
US20220289797A1 (en) Tri-segmented pichinde viruses as vaccine vectors
HK40036451A (en) Tri-segmented arenaviruses as vaccine vectors
HK40106995A (zh) 作为疫苗载体的三区段pichinde病毒
HK40004707B (zh) 作为疫苗载体的三区段pichinde病毒
HK1244034B (en) Tri-segmented arenaviruses as vaccine vectors
HK40004707A (zh) 作为疫苗载体的三区段pichinde病毒
EA046869B1 (ru) Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination